These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy. Fujiwara D, Takahashi K, Suzuki T, Shii M, Nakashima Y, Takekawa S, Yoshida A, Matsuoka T. J Diabetes Investig; 2013 Nov 27; 4(6):618-25. PubMed ID: 24843717 [Abstract] [Full Text] [Related]
3. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test. Iwasaki Y, Kondo K, Hasegawa H, Oiso Y. Diabetes Res; 1994 Nov 27; 25(3):129-37. PubMed ID: 7671552 [Abstract] [Full Text] [Related]
4. Secondary failure to oral hypoglycaemic agents in non-obese patients with non-insulin-dependent diabetes is related to reduced insulin release. Pontiroli AE, Calderara A, Maffi P, Bonisolli L, Carenini A, Piatti PM, Monti LD, Gallus G, Pozza G, Illeni MT. Diabete Metab; 1989 Nov 27; 15(2):79-84. PubMed ID: 2661281 [Abstract] [Full Text] [Related]
5. Increment of serum C-peptide measured by glucagon test closely correlates with human relative beta-cell area. Fujita Y, Kozawa J, Iwahashi H, Yoneda S, Uno S, Yoshikawa A, Okita K, Eguchi H, Nagano H, Imagawa A, Shimomura I. Endocr J; 2015 Nov 27; 62(4):329-37. PubMed ID: 25740613 [Abstract] [Full Text] [Related]
6. A reliable serum C-peptide index for the selection of an insulin regimen to achieve good glycemic control in obese patients with type 2 diabetes: an analysis from a short-term study with intensive insulin therapy. Suzuki T, Takahashi K, Fujiwara D, Shii M, Takekawa S, Matsuoka T. Diabetol Int; 2016 Sep 27; 7(3):235-243. PubMed ID: 30603269 [Abstract] [Full Text] [Related]
8. Pancreatic B-cell function in non-insulin-dependent diabetes mellitus during successive periods of sulfonylurea and insulin treatment: serum C-peptide response to glucagon and urine C-peptide excretion. Hsieh SD, Iwamoto Y, Matsuda A, Kuzuya T. Endocrinol Jpn; 1987 Aug 27; 34(4):561-7. PubMed ID: 3315640 [Abstract] [Full Text] [Related]
9. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, Ikeda K, Takahara S, Nagashima K, Hosokawa M, Seino Y, Inagaki N. J Diabetes Investig; 2011 Aug 02; 2(4):297-303. PubMed ID: 24843502 [Abstract] [Full Text] [Related]
11. [Pancreatic B cell function and glucose intolerance in the elderly]. Nozaki T. Nihon Ika Daigaku Zasshi; 1989 Apr 02; 56(2):153-65. PubMed ID: 2659622 [Abstract] [Full Text] [Related]
12. Serum free C-peptide response to oral glucose loading as a parameter for the monitoring of pancreatic B-cell function in diabetic patients. Hsieh SD, Kanazawa Y, Akanuma Y. Diabetes Res Clin Pract; 1985 Aug 02; 1(2):109-14. PubMed ID: 3915258 [Abstract] [Full Text] [Related]
13. Increment of C-peptide after glucagon injection determines the progressive nature of Japanese type 2 diabetes: a long-term follow-up study. Fukui T, Oono K, Hara N, Yamamoto T, Nagashima M, Naito H, Hirano T. Endocr J; 2013 Aug 02; 60(6):715-24. PubMed ID: 23386398 [Abstract] [Full Text] [Related]
14. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Saisho Y, Kou K, Tanaka K, Abe T, Kurosawa H, Shimada A, Meguro S, Kawai T, Itoh H. Endocr J; 2011 Aug 02; 58(4):315-22. PubMed ID: 21415555 [Abstract] [Full Text] [Related]
16. Correlation of serum CPR to plasma glucose ratio with various indices of insulin secretion and diseases duration in type 2 diabetes. Okuno Y, Sakaguchi K, Komada H, Hashimoto N, Hirota Y, Nakamura T, Ogawa W, Seino S. Kobe J Med Sci; 2013 Apr 18; 59(2):E44-53. PubMed ID: 23756662 [Abstract] [Full Text] [Related]
17. Postprandial serum C-peptide to plasma glucose concentration ratio correlates with oral glucose tolerance test- and glucose clamp-based disposition indexes. Okuno Y, Komada H, Sakaguchi K, Nakamura T, Hashimoto N, Hirota Y, Ogawa W, Seino S. Metabolism; 2013 Oct 18; 62(10):1470-6. PubMed ID: 23831440 [Abstract] [Full Text] [Related]
18. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. Albareda M, Rigla M, Rodríguez-Espinosa J, Caballero A, Chico A, Cabezas R, Carreras G, Pérez A. Diabetes Res Clin Pract; 2005 Jun 18; 68(3):202-6. PubMed ID: 15936461 [Abstract] [Full Text] [Related]
19. Preoperative insulin secretion ability and pancreatic parenchymal thickness as useful parameters for predicting postoperative insulin secretion in patients undergoing pancreaticoduodenectomy. Yoshikawa A, Kozawa J, Okita K, Yoneda S, Okauchi Y, Uno S, Iwahashi H, Ohira T, Takiuchi D, Eguchi H, Takeda Y, Imagawa A, Shimomura I. Endocr J; 2012 Jun 18; 59(5):383-92. PubMed ID: 22374239 [Abstract] [Full Text] [Related]
20. Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus. Iwamoto Y, Kimura T, Tatsumi F, Sugisaki T, Kubo M, Nakao E, Dan K, Wamata R, Iwamoto H, Takahashi K, Sanada J, Fushimi Y, Katakura Y, Shimoda M, Nakanishi S, Mune T, Kaku K, Kaneto H. Front Endocrinol (Lausanne); 2022 Jun 18; 13():871660. PubMed ID: 35574023 [Abstract] [Full Text] [Related] Page: [Next] [New Search]